Jennifer Giltnane MD, PhD

Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm,and her postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University. She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the analysis of high-dimensional clinical data. In addition, she is a co-inventor on several patents for the discovery of scientific methods for assays of protein and signal transduction measurement in breast cancer.

Her clinical training in anatomic and clinical pathology was at Vanderbilt University, where she focused on surgical pathology biobanking, and quality improvement for the diagnosis and management of breast disease. Concurrently, she studied anatomic breast pathology under the guidance of Dr. David Page and Dr. Melinda Sanders. Dr. Giltnane is now a translational pathologist at Genentech, where she leads the development of multiplexed immunofluorescent tissue assays and supports translational oncology and cancer immunology programs of research and early development.